Morganna Freeman, DO, FACP from The Angeles Clinic and Research Institute points out the need for early detection and intervention with many of the side effects seen from immunotherapy treatments.
Using colitis as an example, Freeman discusses what could happen if adverse events go unattended. This could result in long-term hospitalization or more severe medication for the patient. However, earlier reporting and intervention could prevent even hospitalization.
Cemiplimab as Adjuvant Therapy Improves DFS in High-Risk Cutaneous Squamous Cell Carcinoma
January 20th 2025Adjuvant cemiplimab demonstrated a statistically significant improvement in DFS compared to placebo in post-surgical patients with high-risk CSCC, impacting post-operative care considerations.